Related Experiment Video
Updated: Mar 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Clinical Stroke prevention in atrial fibrillation
C Voukalis1, E Shantsila, G Y Lip
1GYH Lip, University of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK.
Insights
Oral anticoagulation therapy, including novel non-vitamin K oral anticoagulants, significantly reduces stroke risk in atrial fibrillation. Balancing bleeding and stroke risks with individualized patient care is crucial for effective management.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Oral anticoagulation therapy is vital for managing atrial fibrillation, reducing ischemic stroke risk and improving patient outcomes.
- Non-vitamin K oral anticoagulants (NOACs) have emerged as key alternatives to vitamin K antagonists (VKAs), transforming stroke prevention strategies.
- Bleeding is a primary complication of antithrombotic therapy, necessitating careful risk-benefit assessment.
Purpose of the Study:
- To review current knowledge on oral anticoagulation in atrial fibrillation patients.
- To guide physicians in managing anticoagulants based on clinical trial and systematic review data.
- To emphasize the importance of balancing ischemic stroke risk against intracranial hemorrhage risk.
Main Methods:
- Systematic review of clinical trials and existing literature.
- Analysis of data on efficacy and safety of oral anticoagulants.
- Evaluation of risk stratification and management strategies.
Main Results:
- Oral anticoagulants significantly reduce ischemic stroke risk in atrial fibrillation.
- NOACs offer an alternative to VKAs with varying profiles.
- Individualized patient management is essential due to heterogeneous risks and preferences.
Conclusions:
- Effective anticoagulation management requires balancing stroke prevention with bleeding risk.
- Physicians must adopt an individualized approach for atrial fibrillation patients on oral anticoagulants.
- Current data support the use of oral anticoagulants for stroke prevention in atrial fibrillation.
Abstract:
Oral anticoagulation therapy has reduced the risk of ischaemic stroke and improved the outcomes for patients with atrial fibrillation considerably. The emergence of the non-vitamin K oral anticoagulants as alternatives to vitamin K antagonists has significantly changed the practice of stroke prevention in atrial fibrillation. As the main complication with antithrombotic therapy is bleeding, physicians should always balance the risk of ischaemic stroke against intracranial haemorrhage and intervene where appropriate to reduce both risks. Individual approach is often mandatory due to heterogeneity of the risks and patient preferences. The purpose of this review is to summarise the current knowledge of the oral anticoagulation therapy in atrial fibrillation patients and guide physicians with the management of anticoagulants based on data from clinical trials and systematic reviews.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

